Palantir’s AI platform boasts 46% operating margins and is deeply embedded in government operations, making it difficult to switch vendors. Recursion’s AI models compress drug discovery from 10 years to weeks, with Big Pharma partnerships validating the approach. JPMorgan Chase processes 65 million AI transactions daily and trades at just 16 times earnings, despite its massive tech budget. These AI stocks are reshaping industries critical to the global economy, with Palantir leading in revenue growth and Recursion revolutionizing drug discovery. JPMorgan is setting the blueprint for AI in finance, with significant advancements in fraud detection and wealth management automation.

Read more at Yahoo Finance: 3 AI Stocks Disrupting Trillion-Dollar Industries